You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. GENETIC CYTOLOGY FOR SURVEILLANCE OF RECURRENT BLADDER CANCER

    SBC: PAPGENE, INC.            Topic: NCI

    This proposal details the development of UroSeqS as a genetic cytology test to extend the utility of routinely collected urine specimens to the detection of recurrent bladder cancer UroSeqS is a genetic cytology assay that achieves sensitivity and specificity through identifying DNA mutations causative of cancer from routinely collected clinical specimens An innovative approach is used toanalyz ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Yeast based Immunotherapy against Clostridium difficile Infection

    SBC: FZATA INC            Topic: NIAID

    Abstract Antibacterial resistance is a global public health crisis Antibiotic resistant Clostridium difficile is responsible for more than deaths in US each year and the infection represents an urgent threat to public health worldwide Of most concern is that the incidence of C difficile infection CDI and disease severity is rapidly increasing in recent years due to the emergence of hy ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Genome Mining the Full Diversity of the Actinomycete Biosynthetic Universe for Neomorph Antibiotic Discovery

    SBC: WARP DRIVE BIO, LLC            Topic: NIAID

    ABSTRACT To combat multidrug resistant bacterial infections novel classes of antibiotics with new mechanisms of action are desperately required Genome mining for novel natural products is quickly replacing traditional approaches to antibiotic discovery Warp Drive Bio has sequenced over actinomycete strain genomes from diverse sources worldwide and our proprietary genomic database conta ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Strategies to Improve Production of a Full Length Native HIV Env Spike

    SBC: CODEX BIOSOLUTIONS            Topic: R

    Project Summary Production of HIV envelope protein Env trimeric gp cleaved to gp gp for clinical studies is a critical objective for vaccine development Its conformational plasticity which allows it to adopt multiple conformational states important for function often makes its expression and purification very difficult Our recent work shows a route for overcoming this probl ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Selection of a device for intranasal administration of a mucosal vaccine for HSV

    SBC: Biomedical Research Models, Inc.            Topic: R

    Globally an estimated of the human population is infected with HSV including andgt of the U S adult population Genital herpes is associated with an increased risk of HIV acquisition and transmission of HSV infection can cause neonatal herpes with high infant mortality HSV infection in the adult population has increased substantially in the past two decades despite the availabil ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Serotype independent therapeutic vaccine for Streptococcus pneumoniae

    SBC: Integrated Biotherapeutics, Inc.            Topic: R

    In the era of growing antibiotic resistancelife threatening infections with several bacterial pathogens are cause for major concernApproved vaccines exist only for a handful of bacterial pathogensEven when a vaccine is available invasive bacterial diseases can occur due to lack of serotype coveragepoor vaccine response among vaccinated populationsor because many simply don t get vaccinatedThusinno ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Harnessing Genomic Information to Engineer Combinatorial Biosynthesis of a Large Polyketide Natural Products Library

    SBC: WARP DRIVE BIO, LLC            Topic: NIAID

    Abstract Natural products have outstanding pharmaceutical pedigree approximately of FDA approved small molecule drugs are derived from plant bacterial or fungal sources To discover new natural products Warp Drive Bio has assembled an enormous proprietary and searchable database of microbial genomes and biosynthetic gene clusters To date our database comprises genomes sequenced ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Screening for rAAV transduction enhancers

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    ABSTRACT Recombinant adeno associated virusrAAVis a promising gene delivery vector for therapeutic and vaccine applicationsbut its low transduction efficacy currently limits its utilityThe primary reasons for low transduction efficacy are as followsiinefficient trafficking of the rAAV genome to the nucleusiiinefficient host cell mediated synthesis of double stranded DNA from the single stranded ge ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Optical Dosimeter guided Photodynamic Therapy

    SBC: PHYSICAL SCIENCES INC.            Topic: 102

    Photodynamic Therapy PDT is a promising modality for cancer treatment Oxygen molecules in the metastable singlet delta state O are believed to be the species that destroys cancerous cells during PDT Despite the benefit of targeted PDT that kills tumors selectively with minimum effect on surrounding healthy tissues at the present time it is difficult if not impossible to predict the res ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Improving delivery of paclitaxel to ovarian cancer via expansile nanoparticles

    SBC: IONIC PHARMACEUTICALS, LLC            Topic: 102

    ABSTRACT A primary challenge in ovarian cancer is preventing tumor recurrence in patients following a resection debulking procedure year survival rate andlt Intraperitoneal IP administration of chemotherapy most notably paclitaxel can improve patient outcomes and prevent local tumor recurrence the principal deterrent to long term survival However despite these modest improvement ...

    SBIR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government